NCT02834013 2026-06-03Nivolumab and Ipilimumab in Treating Patients With Rare TumorsNational Cancer Institute (NCI)Phase 2 Active not recruiting798 enrolled
NCT01738139 2024-03-21Ipilimumab and Imatinib Mesylate in Advanced CancerM.D. Anderson Cancer CenterPhase 1 Completed68 enrolled